CliffBio
small molecule

RENAGEL

SEVELAMER HYDROCHLORIDE

Loss of exclusivity—loss of exclusivity
CompanyGenzyme →See this company's full patent-cliff portfolio

Drug detail

Brand nameRENAGEL
Active ingredientSEVELAMER HYDROCHLORIDE
Strength403MG
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalOctober 1998
Marketing statusDISCN

More from Genzyme

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

RENAGEL patent cliff — loss of exclusivity — | CliffBio